Lupus drug anifrolumab under safety microscope: does it raise infection or cancer risk?

NCT ID NCT07000110

Recruiting now Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 2 times

Summary

This study watches over 3,000 adults with moderate-to-severe lupus to see if the drug anifrolumab increases the risk of serious infections or cancer compared to standard treatments. No new medicine is given—researchers simply analyze health records from people already prescribed anifrolumab. The goal is to better understand the drug's long-term safety in real-world use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Infections neoplasm systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SYSTEMIC LUPUS ERYTHEMATOSUS

Contacts and locations

Locations

Research Site
RECRUITING

Copenhagen, 23000, Denmark
Research Site
RECRUITING

Charenton-le-Pont, 94220, France
Research Site
RECRUITING

Essen, 45128, Germany
Research Site
RECRUITING

Barcelona, 08007, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.